2012-09-18 08:04:39 - Recently published research from Global Markets Direct, "Pulmonary Hypertension - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Pulmonary Hypertension - Pipeline Review, H2 2012', provides an overview of the Pulmonary Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension. 'Pulmonary Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463895_pulmonary_hypertension_pipeline_revie ..


Note*: Certain sections in the report may be removed or

altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Pulmonary Hypertension.
* A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Pulmonary Hypertension pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Pulmonary Hypertension therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Pulmonary Hypertension Therapeutic Products under Development, Key Players in Pulmonary Hypertension Therapeutics, Pulmonary Hypertension Pipeline Overview, Pulmonary Hypertension Pipeline, Pulmonary Hypertension Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Pulmonary Hypertension
Pulmonary Hypertension Therapeutics under Development by Companies
Pulmonary Hypertension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Pulmonary Hypertension Therapeutics - Products under Development by Companies
Pulmonary Hypertension Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Pulmonary Hypertension Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Boehringer Ingelheim GmbH
Sanofi-Aventis
Gilead Sciences, Inc.
FibroGen, Inc.
Novartis AG
Actelion Ltd
InterMune, Inc.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Celgene Corporation
Bayer AG
Geron Corporation
Oncothyreon Inc
Compugen Ltd.
LTT Bio-Pharma Co., Ltd.
axxonis Pharma AG
Auspex Pharmaceuticals
Promedior, Inc.
Mondobiotech Holding AG
Conatus Pharmaceuticals Inc.
GenKyoTex S.A.
Stromedix, Inc.
ImmuneRegen BioSciences, Inc.
ImmuneWorks, LLC
Pacific Therapeutics Ltd.
Pulmonary Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BAY 63-2521 - Drug Profile
BAY 63-2521 - Drug Profile
GC1008 - Drug Profile
JNK CC-930 - Drug Profile
Esbriet - Drug Profile
NBT-485 - Drug Profile
FG-3019 - Drug Profile
Macitentan - Drug Profile
Homspera - Drug Profile
PC-SOD - Drug Profile
CGEN-25009 - Drug Profile
PX-866 - Drug Profile
Vargatef - Drug Profile
PRM-151 - Drug Profile
STX-100 - Drug Profile
Selexipag - Drug Profile
QAX-576 - Drug Profile
DHEA - Drug Profile
IW001 - Drug Profile
Prednisone + Azathioprine + N-Acetylcysteine - Drug Profile
Sildenafil - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463895&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.